Prescribing Paradigm Shift? Applying the 2019 European Society of CardiologyâLed Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for SodiumâGlucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Caparrotta, Thomas M., Blackbourn, Luke A.K., McGurnaghan, Stuart J., Chalmers, John, Lindsay, Robert, McCrimmon, Rory, McKnight, John, Wild, Sarah, Petrie, John R., Philip, Sam, McKeigue, Paul M., WeЖурнал:
Diabetes Care
DOI:
10.2337/dc20-0120
Date:
June, 2020
Файл:
PDF, 796 KB
2020
File converter
Більше результатів пошуку
More benefits 
